Apremilast, Methotrexate and NB ‐ UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison
Photodermatology, Photoimmunology & Photomedicine · 2026
DOI: 10.1111/phpp.70066 ↗At a glance
Beobachtungsstudie in Photodermatology, Photoimmunology & Photomedicine, 2026. Written by Alessia Balestrino and 5 co-authors. Institution: Department of Medicine Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy. Major MEDLINE topics: Psoriasis, Methotrexate, Thalidomide, Ultraviolet Therapy. 18 references.
Abstract (original language)
Background
Selecting the most appropriate therapy for psoriasis remains challenging due to variability in disease severity and individual patient factors. Among non‐biological treatments, methotrexate (MTX), apremilast (APRE), and narrowband UVB (NB‐UVB) phototherapy are widely utilized.
Objective
To compare, under real‐world conditions, the clinical efficacy, quality of life, patient satisfaction, and immunomodulatory effects of APRE, MTX, and NB‐UVB in moderate‐to‐severe plaque psoriasis over 16 weeks.
Methods
This pilot prospective observational cohort study included 37 patients treated independently with APRE ( n = 13), MTX ( n = 15), or NB‐UVB ( n = 9). Clinical outcomes were assessed using PASI, BSA, PGA, DLQI scores, and the TSQM‐9 questionnaire. Systemic and local inflammation were assessed by multiplex cytokine assays and RT‐PCR in vivo and in vitro.
Results
By Week 16, significant improvements were observed in PASI, DLQI, and PGA scores across all groups, with no statistically significant differences in efficacy between treatments. A trend toward a greater response was observed for both MTX and APRE. APRE treatment demonstrated a tendency for more pronounced modulation of pro‐inflammatory cytokines compared to both MTX and NB‐UVB. NB‐UVB increased the anti‐inflammatory IL‐10. Combination therapy with NB‐UVB and APRE further increased IL‐10 levels and reduced IL‐33 in HaCaT cells, suggesting synergistic immunomodulatory effects; however, the clinical relevance of these in vitro findings remains unproven and requires further investigation.
Conclusion
APRE, MTX, and NB‐UVB each improved clinical outcomes with comparable overall efficacy and good tolerability in this pilot cohort. Each therapeutic regime showed distinct immunomodulatory profiles with good tolerability. Personalized treatment strategies, including potential combinations, may optimize outcomes for patients with moderate‐to‐severe psoriasis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
- Dermatology Unit, A. Tortora Hospital, Pagani, Salerno, Italy.
- University of Salerno, Postgraduate School in Clinical Pathology and Clinical Biochemistry, Salerno, Italy.
ORCID profiles: Alessia Balestrino
Cite
APA
Balestrino, A., Lembo, S., Manzo, R., Battipaglia, M. G., Nigro, A., & Raimondo, A. (2026). Apremilast, Methotrexate and NB ‐ UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.70066
Vancouver
Balestrino A, Lembo S, Manzo R, Battipaglia MG, Nigro A, Raimondo A. Apremilast, Methotrexate and NB ‐ UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison. Photodermatology, Photoimmunology & Photomedicine. 2026. doi:10.1111/phpp.70066
BibTeX
@article{Balestrino2026,
author = {Balestrino, Alessia and Lembo, Serena and Manzo, Raffaella and Battipaglia, Maria Grazia and Nigro, Annunziata and Raimondo, Annunziata},
title = {Apremilast, Methotrexate and NB ‐ UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2026},
doi = {10.1111/phpp.70066}
}
EUVIMED